{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:37:47Z","timestamp":1794476267349,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-023-05289-3","type":"journal-article","created":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T08:03:11Z","timestamp":1677312191000},"page":"969-973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-9394","authenticated-orcid":false,"given":"Alexandros","family":"Panagiotopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-6918","authenticated-orcid":false,"given":"Christos","family":"Koutsianas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5275-8639","authenticated-orcid":false,"given":"Nikolaos","family":"Kougkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Moschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-1362","authenticated-orcid":false,"given":"Vasiliki-Kalliopi","family":"Bournia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-2055","authenticated-orcid":false,"given":"Sousana","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G.","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-3863","authenticated-orcid":false,"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P.","family":"Sfikakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"5289_CR1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/8qxo80","author":"C Gialouri","year":"2022","unstructured":"Gialouri C, Evangelatos G, Zhao SS et al (2022) Depression and anxiety in a real-world psoriatic arthritis longitudinal study: should we focus more on patients\u2019 perception? Clin Exp Rheumatol. https:\/\/doi.org\/10.55563\/clinexprheumatol\/8qxo80","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"5289_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","volume":"72","author":"A Jamnitski","year":"2013","unstructured":"Jamnitski A, Symmons D, Peters MJL, Sattar N, MciInnes I, Nurmohamed MT (2013) Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 72(2):211\u2013216. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201194","journal-title":"Ann Rheum Dis"},{"key":"5289_CR3","doi-asserted-by":"publisher","first-page":"1759720","DOI":"10.1177\/1759720X20976975","volume":"12","author":"GE Fragoulis","year":"2020","unstructured":"Fragoulis GE, Evangelatos G, Tentolouris N et al (2020) Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis. 12:1759720. https:\/\/doi.org\/10.1177\/1759720X20976975","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"6","key":"5289_CR4","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):7001\u20137712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5289_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5289_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL et al (2016) 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"5289_CR7","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s12325-017-0617-5","volume":"34","author":"B Chastek","year":"2017","unstructured":"Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W (2017) Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. Adv Ther 34(11):2422\u20132435. https:\/\/doi.org\/10.1007\/s12325-017-0617-5","journal-title":"Adv Ther"},{"issue":"12","key":"5289_CR8","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1136\/annrheumdis-2014-205325","volume":"73","author":"MH Schiff","year":"2014","unstructured":"Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73(12):2174\u20132177. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205325","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5289_CR9","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1001\/jama.2016.13512","volume":"316","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Brocq O, Perdriger A et al (2016) Non\u2013TNF-targeted biologic vs a second anti-tnf drug to treat rheumatoid arthritis in patients with insufficient response to a first Anti-TNF Drug. JAMA 316(11):1172. https:\/\/doi.org\/10.1001\/jama.2016.13512","journal-title":"JAMA"},{"issue":"9","key":"5289_CR10","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL (2014) Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology 53(9):1664\u20131668. https:\/\/doi.org\/10.1093\/rheumatology\/keu158","journal-title":"Rheumatology"},{"issue":"12","key":"5289_CR11","doi-asserted-by":"publisher","first-page":"102398","DOI":"10.1016\/j.autrev.2019.102398","volume":"18","author":"A Rubbert-Roth","year":"2019","unstructured":"Rubbert-Roth A, Szab\u00f3 MZ, Kedves M, Nagy G, Atzeni F, Sarzi-Puttini P (2019) Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. Autoimmun Rev 18(12):102398. https:\/\/doi.org\/10.1016\/j.autrev.2019.102398","journal-title":"Autoimmun Rev"},{"issue":"1","key":"5289_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA (2017) Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum 47(1):29\u201337. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.001","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"5289_CR13","doi-asserted-by":"publisher","first-page":"000880","DOI":"10.1136\/rmdopen-2018-000880","volume":"5","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Karki C, Liu M et al (2019) Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open 5(1):000880. https:\/\/doi.org\/10.1136\/rmdopen-2018-000880","journal-title":"RMD Open"},{"issue":"2","key":"5289_CR14","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.1111\/dth.12793","volume":"32","author":"G Damiani","year":"2019","unstructured":"Damiani G, Conic RRZ, de Vita V et al (2019) When IL-17 inhibitors fail: Real-life evidence to switch from secukinumab to adalimumab or ustekinumab. Dermatol Ther 32(2):12793. https:\/\/doi.org\/10.1111\/dth.12793","journal-title":"Dermatol Ther"},{"key":"5289_CR15","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2147\/BTT.S326792","volume":"15","author":"J Berman","year":"2021","unstructured":"Berman J, Furer V, Berman M et al (2021) Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: Real-Life experience from a resistant population. Biologics 15:463\u2013470. https:\/\/doi.org\/10.2147\/BTT.S326792","journal-title":"Biologics"},{"issue":"1","key":"5289_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/24755303211063841\/ASSET\/IMAGES\/LARGE\/10.1177_24755303211063841-FIG1.JPEG","volume":"7","author":"S Darabian","year":"2022","unstructured":"Darabian S, Badii M, Dutz JP, Chan J (2022) A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis. J Psoriasis Psoriatic Arthritis 7(1):13\u201316. https:\/\/doi.org\/10.1177\/24755303211063841\/ASSET\/IMAGES\/LARGE\/10.1177_24755303211063841-FIG1.JPEG","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"2","key":"5289_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/S00296-021-05065-1\/TABLES\/1","volume":"42","author":"M Bare\u0161i\u0107","year":"2022","unstructured":"Bare\u0161i\u0107 M, Smiljani\u0107 Tomi\u010devi\u0107 L, Ani\u0107 B, Mayer M (2022) Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatol Int 42(2):365\u2013370. https:\/\/doi.org\/10.1007\/S00296-021-05065-1\/TABLES\/1","journal-title":"Rheumatol Int"},{"issue":"8","key":"5289_CR18","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5289_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jaad.2020.07.085","volume":"84","author":"N Loft","year":"2021","unstructured":"Loft N, Halling AS, Egeberg A, Skov L (2021) Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol 84(1):130\u2013138. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.085","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"5289_CR20","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1111\/jdv.18381","volume":"36","author":"E Sotiriou","year":"2022","unstructured":"Sotiriou E, Bakirtzi K, Papadimitriou I et al (2022) Real-life intraclass switch among <scp>IL<\/scp> -17 inhibitors in psoriasis: results from a single-centre, 24-week, retrospective study. J Eur Acad Dermatology Venereol 36(11):e952\u2013e953. https:\/\/doi.org\/10.1111\/jdv.18381","journal-title":"J Eur Acad Dermatology Venereol"},{"issue":"4","key":"5289_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/annrheumdis-2016-209853","volume":"76","author":"DR Jadon","year":"2017","unstructured":"Jadon DR, Sengupta R, Nightingale A et al (2017) Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann Rheum Dis 76(4):701\u2013707. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209853","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5289_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.31138\/mjr.33.1.142","volume":"33","author":"C Lopez-Medina","year":"2022","unstructured":"Lopez-Medina C, Ziade N (2022) Axial Disease in Psoriatic Arthritis: how can we Define it, and does it have an Impact on Treatment? Mediterr J Rheumatol 33(1):142. https:\/\/doi.org\/10.31138\/mjr.33.1.142","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"5289_CR23","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E et al (2021) Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 80(5):582\u2013590. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5289_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","volume":"47","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C et al (2017) Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum 47(2):183\u2013192. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.03.008","journal-title":"Semin Arthritis Rheum"},{"issue":"16","key":"5289_CR25","doi-asserted-by":"publisher","first-page":"25300","DOI":"10.1097\/MD.0000000000025300","volume":"100","author":"A Ariani","year":"2021","unstructured":"Ariani A, Santilli D, Mozzani F et al (2021) Cycling or swap biologics and small molecules in psoriatic arthritis. Medicine (Baltimore) 100(16):25300. https:\/\/doi.org\/10.1097\/MD.0000000000025300","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"5289_CR26","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/BJD.16497","volume":"178","author":"C Paul","year":"2018","unstructured":"Paul C (2018) Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol 178(5):1003\u20131005. https:\/\/doi.org\/10.1111\/BJD.16497","journal-title":"Br J Dermatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05289-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-023-05289-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-023-05289-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:00:27Z","timestamp":1680746427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-023-05289-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["5289"],"URL":"https:\/\/doi.org\/10.1007\/s00296-023-05289-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,25]]},"assertion":[{"value":"18 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Panagiotopoulos, speaker fees\/honoraria: none, C. Koutsianas, speaker fees\/honoraria: Abbvie, Pfizer, UCB, Novartis, Aenorasis, Eli-Lilly, Genesis\u2014Pharma, N. Kougkas, speaker fees\/honoraria: Abbvie, Pfizer, UCB, Novartis, Aenorasis, UCB, Eli-Lilly, Roche, Genesis, Viatris, MSD, D. Moschou, speaker fees\/honoraria: none, V-K Bournia, speaker fees\/honoraria: Abbvie, Vianex, S. Gazi, speaker fees\/honoraria: none, M.G Tektonidou, speaker fees\/honoraria: Genesis\u2014Pharma, UCB, GlaxoSmithKline, MSD, Novartis, Faran, D. Vassilopoulos, speaker fees\/honoraria: Abbvie, Aenorasis, Amgen, Boehringer Ingelheim, Janssen, Genesis\u2014Pharma, GSK, MSD, Pfizer, Roche, Sobi, UCB, Eli-Lilly, P.P Sfikakis, speaker fees\/honoraria: Actelion, Pfizer, Genesis\u2014Pharma, MSD, UCB, Boehringer Ingelheim, Aenorasis, Gilead, Abbvie, Novartis, Eli-Lilly, G.E Fragoulis, speaker fees\/honoraria: Abbvie, Pfizer, UCB, Novartis, Aenorasis, UCB, Janssen, Eli-Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}